Developer of monoclonal antibody therapeutics created to treat cancer. The company's lead product candidate, RAV12, targets adenocarcinomas and simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them, identifying novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane for the treatment of gastrointestinal and other cancers.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Merger/Acquisition | 17-Jul-2008 | $25M | 00000 | 0000 | Completed | Generating Revenue/Not Profitable |
9. Merger/Acquisition | 01-Mar-2008 | Cancelled | Clinical Trials - General | |||
8. Convertible Debt | 12-Nov-2007 | 00.00 | 00000 | Completed | Generating Revenue/Not Profitable | |
7. Later Stage VC (Series D) | 12-Oct-2005 | 000.00 | 00000 | Completed | Clinical Trials - General | |
6. Later Stage VC | 28-Oct-2004 | 00000 | 00000 | Completed | Generating Revenue | |
5. Later Stage VC (Series C) | 13-Mar-2003 | 000.00 | 00000 | Completed | Pre-Clinical Trials | |
4. Later Stage VC (Series C) | 02-Jan-2003 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
3. Early Stage VC (Series B) | 08-Jan-2001 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
2. Early Stage VC (Series A) | Completed | Pre-Clinical Trials | ||||
1. Accelerator/Incubator | 01-Jan-2000 | Completed | Pre-Clinical Trials |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Bear Stearns Health InnoVentures Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
CIDC Consultants | Venture Capital | Minority | 000 0000 | 000000 0 | |
China Investment & Development | Venture Capital | Minority | 000 0000 | 000000 0 | |
Cogene Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
GE Life Science and Technology Finance | Corporation | Minority | 000 0000 | 000000 0 |